CR20170167A - Derivados de imidazol pentacíclicos fusionados - Google Patents

Derivados de imidazol pentacíclicos fusionados

Info

Publication number
CR20170167A
CR20170167A CR20170167A CR20170167A CR20170167A CR 20170167 A CR20170167 A CR 20170167A CR 20170167 A CR20170167 A CR 20170167A CR 20170167 A CR20170167 A CR 20170167A CR 20170167 A CR20170167 A CR 20170167A
Authority
CR
Costa Rica
Prior art keywords
disorders
fided
pentacyclic
imidazol derivatives
derivatives
Prior art date
Application number
CR20170167A
Other languages
English (en)
Inventor
Jag Paul Heer
Zhaoning Zhu
Daniel Christopher Brookings
Dominique Louis Léon Swinnen
Laurent; Schio
Yves Evrard
Coss Malcolm Mac
Matthew Duncan Selby
Yann Foricher
Haro Garcia Teresa De
Joanna Rachel Quincey
Mengyang Xuan
Michael Alan Shaw
Bruno Filoche-Romme
Michael Deligny
Mark Daniel Calmiano
Martin Clive Hutchings
James Andrew Johnson
Jean Keyaerts
Sophie Jadot
Original Assignee
Sanofi Sa
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa, Ucb Biopharma Sprl filed Critical Sanofi Sa
Publication of CR20170167A publication Critical patent/CR20170167A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Una serie de derivados de imidazol pentacíclicos fusionados, que son potentes moduladores de la actividad de TNFa humano, son en consecuencia beneficiosos en el tratamiento y/o prevención de diferentes enfermedades humanas, que incluyen trastornos autoinmunológicos e inflamatorios; trastornos neurológicos y neurodegenerativos; trastornos de dolor y nociceptivos; trastornos cardiovasculares; trastornos metabólicos; trastornos oculares; y trastornos oncológicos.
CR20170167A 2014-10-03 2015-10-02 Derivados de imidazol pentacíclicos fusionados CR20170167A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP14290299 2014-10-03
EP15162641 2015-04-07
EP15171036 2015-06-08
PCT/EP2015/072868 WO2016050975A1 (en) 2014-10-03 2015-10-02 Fused pentacyclic imidazole derivatives

Publications (1)

Publication Number Publication Date
CR20170167A true CR20170167A (es) 2017-08-10

Family

ID=54238452

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20170167A CR20170167A (es) 2014-10-03 2015-10-02 Derivados de imidazol pentacíclicos fusionados

Country Status (36)

Country Link
US (3) US10202405B2 (es)
EP (1) EP3201196B1 (es)
JP (1) JP6629847B2 (es)
KR (1) KR102442235B1 (es)
CN (1) CN107108672B (es)
AP (1) AP2017009809A0 (es)
AU (1) AU2015326798B2 (es)
BR (1) BR112017006669B1 (es)
CA (1) CA2962826C (es)
CL (1) CL2017000787A1 (es)
CO (1) CO2017003331A2 (es)
CR (1) CR20170167A (es)
DK (1) DK3201196T3 (es)
EA (1) EA032839B1 (es)
EC (1) ECSP17027306A (es)
ES (1) ES2885432T3 (es)
GT (1) GT201700044A (es)
HR (1) HRP20211605T1 (es)
HU (1) HUE056133T2 (es)
IL (1) IL251147B (es)
LT (1) LT3201196T (es)
MA (1) MA40770B1 (es)
MX (1) MX2017004201A (es)
MY (1) MY181019A (es)
PE (1) PE20170693A1 (es)
PH (1) PH12017500414B1 (es)
PL (1) PL3201196T3 (es)
RS (1) RS62423B1 (es)
SG (1) SG11201701796XA (es)
SI (1) SI3201196T1 (es)
TN (1) TN2017000083A1 (es)
TW (1) TWI719949B (es)
UA (1) UA120764C2 (es)
UY (1) UY36341A (es)
WO (1) WO2016050975A1 (es)
ZA (1) ZA201701946B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2885432T3 (es) * 2014-10-03 2021-12-13 Ucb Biopharma Sprl Derivados de imidazol pentacíclicos condensados
WO2016168633A1 (en) 2015-04-17 2016-10-20 Abbvie Inc. Indazolones as modulators of tnf signaling
TW201702247A (zh) 2015-04-17 2017-01-16 艾伯維有限公司 作為ｔｎｆ信號傳遞調節劑之吲唑酮
UY36630A (es) 2015-04-17 2016-11-30 Abbvie Inc Moduladores tricíclicos de la señalización por tnf
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
CN109195968B (zh) 2016-04-01 2022-02-11 Ucb生物制药私人有限公司 作为tnf活性调节剂的稠合五环咪唑衍生物
JP6968092B2 (ja) * 2016-04-01 2021-11-17 ユーシービー バイオファルマ エスアールエル Ｔｎｆ活性のモジュレーターとしての縮合五環式イミダゾール誘導体
EA201892149A1 (ru) 2016-04-01 2019-04-30 Юсб Байофарма Спрл Конденсированные пентациклические производные имидазола в качестве модуляторов активности tnf
CN109219609B (zh) * 2016-04-01 2022-02-01 Ucb生物制药私人有限公司 作为tnf活性调节剂的稠合六环咪唑衍生物
GB201620948D0 (en) 2016-12-09 2017-01-25 Ucb Biopharma Sprl Therapeutic agents
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope
WO2018167176A1 (en) 2017-03-15 2018-09-20 Ucb Biopharma Sprl Fused pentacyclic imidazole derivatives as modulators of tnf activity
TWI801378B (zh) * 2017-04-25 2023-05-11 比利時商Ｕｃｂ生物製藥公司 作為tnf活性調節劑之稠合五環咪唑衍生物
PT3870586T (pt) 2018-10-24 2023-07-19 UCB Biopharma SRL Derivados de imidazole pentacíclico fundido como moduladores da atividade do tnf
CN113683505A (zh) * 2021-09-29 2021-11-23 厦门大华本安化工安全研究院有限公司 一种含氧代环丁基的羧酸酯类化合物的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0449649A3 (en) 1990-03-30 1992-09-02 Arizona Board Of Regents, Arizona State University Antineoplastic quinones and methods of using same
FR2832711B1 (fr) 2001-11-26 2004-01-30 Warner Lambert Co Derives de triazolo [4,3-a] pyrido [2,3-d] pyrimidin-5-ones, compositions les contenant, procede de preparation et utilisation
EP1603926A1 (en) 2003-03-10 2005-12-14 Pfizer Inc. Phosphate/sulfate ester compounds and pharmaceutical compositions for inhibiting protein interacting nima (pin1)
DE102008030206A1 (de) 2008-06-25 2009-12-31 Bayer Schering Pharma Aktiengesellschaft 3-Cyanoalky- und 3-Hydroxyalkyl-Indole und ihre Verwendung
AR088728A1 (es) 2011-03-25 2014-07-02 Bristol Myers Squibb Co Moduladores de lxr como prodroga de imidazol
JP5977344B2 (ja) 2011-06-20 2016-08-24 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ ジャイレースおよびトポイソメラーゼ阻害剤のリン酸エステル
US9550737B2 (en) * 2012-06-11 2017-01-24 Ucb Biopharma Sprl TNF -α modulating benzimidazoles
CN104619709B (zh) * 2012-07-13 2016-11-09 Ucb生物制药私人有限公司 作为tnf活性调节剂的咪唑并吡啶衍生物
GB201212513D0 (en) * 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents
WO2015059668A1 (en) 2013-10-25 2015-04-30 Novartis Ag Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
GB201321729D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321728D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
IL303422A (en) 2014-04-15 2023-08-01 Vertex Pharma Pharmaceutical preparations for the treatment of diseases related to cystic fibrosis transmembrane conductance regulator modulators
ES2885432T3 (es) * 2014-10-03 2021-12-13 Ucb Biopharma Sprl Derivados de imidazol pentacíclicos condensados

Also Published As

Publication number Publication date
EA032839B1 (ru) 2019-07-31
EP3201196A1 (en) 2017-08-09
TN2017000083A1 (en) 2018-07-04
HUE056133T2 (hu) 2022-01-28
KR20170068503A (ko) 2017-06-19
ZA201701946B (en) 2018-07-25
SI3201196T1 (sl) 2021-12-31
NZ730256A (en) 2021-05-28
UY36341A (es) 2016-04-29
BR112017006669A2 (pt) 2017-12-26
JP2017531648A (ja) 2017-10-26
PH12017500414A1 (en) 2017-07-17
AU2015326798A1 (en) 2017-04-06
RS62423B1 (sr) 2021-10-29
DK3201196T3 (da) 2021-09-06
IL251147A0 (en) 2017-04-30
AP2017009809A0 (en) 2017-03-31
TW201629067A (zh) 2016-08-16
US20170305932A1 (en) 2017-10-26
MA40770B1 (fr) 2021-11-30
US10202405B2 (en) 2019-02-12
US10906919B2 (en) 2021-02-02
CN107108672A (zh) 2017-08-29
ES2885432T3 (es) 2021-12-13
MY181019A (en) 2020-12-16
CO2017003331A2 (es) 2017-09-29
EP3201196B1 (en) 2021-07-28
HRP20211605T1 (hr) 2022-01-21
TWI719949B (zh) 2021-03-01
CL2017000787A1 (es) 2017-11-24
US20190367535A1 (en) 2019-12-05
UA120764C2 (uk) 2020-02-10
US11912721B2 (en) 2024-02-27
KR102442235B1 (ko) 2022-09-08
PH12017500414B1 (en) 2017-07-17
JP6629847B2 (ja) 2020-01-15
SG11201701796XA (en) 2017-04-27
CA2962826C (en) 2023-08-08
CN107108672B (zh) 2019-11-08
AU2015326798B2 (en) 2020-01-02
MA40770A (fr) 2021-03-24
GT201700044A (es) 2019-09-09
EA201790734A1 (ru) 2017-09-29
PL3201196T3 (pl) 2022-01-03
BR112017006669B1 (pt) 2023-04-18
LT3201196T (lt) 2021-09-27
ECSP17027306A (es) 2017-05-31
IL251147B (en) 2020-05-31
MX2017004201A (es) 2017-05-30
WO2016050975A1 (en) 2016-04-07
US20210155637A1 (en) 2021-05-27
CA2962826A1 (en) 2016-04-07
PE20170693A1 (es) 2017-06-13

Similar Documents

Publication Publication Date Title
CR20170167A (es) Derivados de imidazol pentacíclicos fusionados
BR112016012997A2 (pt) Derivados de benzimidazóis tricíclicos fundidos como moduladores de atividade de tnf
HRP20190117T1 (hr) iRNK TERAPIJA ZA LIJEČENJE BOLESTI OKA
BR112016012242A2 (pt) Derivados de tetra-hidroimidazopiridina como moduladores de atividade de tnf
DK3349844T3 (da) Indretning til okulær mikrostrømsstimulationsterapi
BR112016012990A2 (pt) Derivados de imidazol tricíclicos fundidos como moduladores de atividade de tnf
WO2015136016A3 (en) Therapeutic combinations with estrogen receptor modulators
BR112016012258A2 (pt) Derivados de tetra-hidrobenzimidazol como moduladores de atividade de tnf
EP3510175A4 (en) OPTIMIZATION OF THERAPEUTIC OPTIONS IN PERSONALIZED MEDICINE
UY36171A (es) Derivados heteroaromáticos bicíclicos fusionados como inhibidores de quinasa
BR112016012261A2 (pt) Derivados de tetra-hidroimidazopiridina como moduladores de atividade de tnf
EP3188721A4 (en) Human therapeutic agents
MA53568A (fr) Médicaments pour le traitement de maladies ophtalmiques
BR112018069936A2 (pt) derivados de imidazol pentacíclicos fundidos como moduladores de atividade do tnf
BR112018069941A2 (pt) derivados de imidazol pentacíclicos fundidos como moduladores de atividade do tnf
BR112018069937A2 (pt) derivados de imidazol hexacíclicos fundidos como moduladores de atividade do tnf
EA201892149A1 (ru) Конденсированные пентациклические производные имидазола в качестве модуляторов активности tnf
CO2019012856A2 (es) Derivados de imidazol pentacíclico fusionado como moduladores de la actividad de tnf
EP3302530A4 (en) Cdh26 based therapeutic agents and their use
EP3470109A4 (en) THERAPEUTIC DEVICE USING AN ENDOSCOPE INTERWORKING ELECTRODE
ZA202001418B (en) Therapeutic indazoles
EP3655106A4 (en) COMBINED INGREDIENTS THERAPY
EP3356561A4 (en) THERAPEUTIC AND DIAGNOSTIC METHODS FOR AUTOIMMUNE DISEASES AND / OR INFLAMMATIONS
EP3280261A4 (en) Anticancer therapeutic agents
IL271062A (en) Device using electrotherapy for the relief of hemorrhoid inflammation